[1] WENCEWICZ T A. Crossroads of antibiotic resistance and biosynthesis [J]. J Mol Biol, 2019, 431(18):3370-3399.
[2] BLOOS F, RÜDDEL H, THOMAS-RÜDDEL D, et al. Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial [J]. Intensive Care Med, 2017, 43(11):1602-1612.
[3] TSAI D, LIPMAN J, ROBERTS J A. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill [J]. Curr Opin Crit Care, 2015, 21(5):412-420.
[4] BIDELL M R, LODISE T P. Suboptimal clinical response rates with newer antibiotics among patients with moderate renal impairment: review of the literature and potential pharmacokinetic and pharmacodynamic considerations for observed findings [J]. Pharmacotherapy, 2018, 38(12):1205-1215.
[5] ABDUL-AZIZ M H, ALFFENAAR J C, BASSETTI M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper [J]. Intensive Care Med, 2020, 46(6):1127-1153.
[6] TOOKE C L, HINCHLIFFE P, BRAGGINTON E C, et al. β-lactamases and β-lactamase inhibitors in the 21st century [J]. J Mol Biol, 2019, 431(18):3472-3500.
[7] SHIRLEY M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections [J]. Drugs, 2018, 78(6):675-692.
[8] ZASOWSKI E J, RYBAK J M, RYBAK M J. The β-lactams strike back: ceftazidime-avibactam [J]. Pharmacotherapy, 2015, 35(8):755-770.
[9] ABDULLA A, DIJKSTRA A, HUNFELD N G M, et al. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT) [J]. Crit Care, 2020, 24(1):1-12.
[10] ROBERTS J A, PAUL S K, AKOVA M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? [J]. Clin Infect Dis, 2014, 58(8):1072-1083.
[11] JACOBS A, TACCONE F S, ROBERTS J A, et al. β-lactam dosage regimens in septic patients with augmented renal rlearance [J]. Antimicrob Agents Chemother, 2018, 62(9):e02534-17. Doi: 10.1128/AAC.02534-17.
[12] ROBERTS J A, JOYNT G M, LEE A, et al. The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational sampling antibiotics in renal replacement therapy study [J]. Clin Infect Dis, 2021, 72(8):1369-1378.
[13] PINNER N A, TAPLEY N G, BARBER K E, et al. Effect of obesity on clinical failure of patients treated with β-lactams [J]. Open Forum Infect Dis, 2021, 8(8):ofab212. Doi: 10.1093/ofid/ofab212.
[14] JAGER N G L, VAN HEST R M, LIPMAN J, et al. Antibiotic exposure at the site of infection: principles and assessment of tissue penetration [J]. Expert Rev Clin Pharmacol, 2019, 12(7):623-634.
[15] RICHTER D C, HEININGER A, CHIRIAC U, et al. Antibiotic stewardship and therapeutic drug monitoring of β-lactam antibiotics: is there a link? an opinion paper [J]. Ther Drug Monit, 2022, 44(1):103-111.
[16] FRATONI A J, NICOLAU D P, KUTI J L. A guide to therapeutic drug monitoring of β-lactam antibiotics [J]. Pharmacotherapy, 2021, 41(2):220-233.
[17] AL-SHAER M H, RUBIDO E, CHERABUDDI K, et al. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients [J]. J Antimicrob Chemother, 2020, 75(12):3644-3651.
[18] GUILHAUMOU R, BENABOUD S, BENNIS Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR) [J]. Crit Care, 2019, 23(1):1-20.
[19] DHAESE S, VAN VOOREN S, BOELENS J, et al. Therapeutic drug monitoring of β-lactam antibiotics in the ICU [J]. Expert Rev Anti Infect Ther, 2020, 18(11):1155-1164.
[20] ABDULLA A, EWOLDT T M J, HUNFELD N G M, et al. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial [J]. BMC Infect Dis, 2020, 20(1):1-9.
[21] LIEBCHEN U, SALLETMEIER H, KALLEE S, et al. Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study [J]. Sci Rep, 2021, 11(1):1-6.
[22] LI L, LI X, XIA Y, et al. Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy [J]. Front Pharmacol, 2020, 11:580163. Doi: 10.3389/fphar.2020.580163.
[23] SOUKUP P, FAUST A C, EDPUGANTI V, et al. Steady-state ceftazidime-avibactam serum concentrations and dosing recommendations in a critically ill patient being treated for pseudomonas aeruginosa pneumonia and undergoing continuous venovenous hemodiafiltration [J]. Pharmacotherapy, 2019, 39(12):1216-1222.
[24] VEILLETTE J J, TRUONG J, FORLAND S C. Pharmacokinetics of ceftazidime-avibactam in two patients with KPC-producing klebsiella pneumoniae bacteremia and renal impairment [J]. Pharmacotherapy, 2016, 36(11):e172-e177.
[25] WENZLER E, BUNNELL K L, BLEASDALE S C, et al. Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration [J]. Antimicrob Agents Chemother, 2017, 61(7):e00464-17. Doi: 10.1128/AAC.00464-17.
[26] MATUSIK E, LEMTIRI J, WABONT G, et al. Beta-lactam dosing during continuous renal replacement therapy: a survey of practices in french intensive care units [J]. BMC Nephrol, 2022, 23(1):1-10.
[27] FLUME P A, O'SULLIVAN B P, ROBINSON K A, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health [J]. Am J Respir Crit Care Med, 2007, 176(10):957-969.
[28] BILAL H, TAIT J R, LANG Y, et al. Simulated intravenous versus inhaled tobramycin with and without intravenous ceftazidime evaluated against hypermutable pseudomonas aeruginosa via a dynamic biofilm model and mechanism-based modeling [J]. Antimicrob Agents Chemother, 2022: aac0220321. Doi: 10.1128/aac.02203-21.
[29] BENSMAN T J, WANG J, JAYNE J, et al. Pharmacokinetic-pharmacodynamic target attainment analyses to determine optimal dosing of ceftazidime-avibactam for the treatment of acute pulmonary exacerbations in patients with cystic fibrosis [J]. Antimicrob Agents Chemother, 2017, 61(10):e00988-17. Doi: 10.1128/AAC.00988-17.
[30] ZHANG H L, HUANG Z G, QIU Y, et al. Optimizing vancomycin regimen in children with MRSA infections based on PK/PD model and Monte Carlo simulation [J]. Chin Pharm J(中国药学杂志), 2017, 52(3):217-220.
[31] NICOLAU D P, SIEW L, ARMSTRONG J, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens [J]. J Antimicrob Chemother, 2015, 70(10):2862-2869.
[32] COWART M C, FERGUSON C L. Optimization of aztreonam in combination with ceftazidime/avibactam in a cystic fibrosis patient with chronic stenotrophomonas maltophilia pneumonia using therapeutic drug monitoring: a case study [J]. Ther Drug Monit, 2021, 43(2):146-149.
[33] THOMPSON R Z, MARTIN C A, BURGESS D R, et al. Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients [J]. J Cyst Fibros, 2016, 15(5):660-663.
[34] PANDIT R, CHEN L, GÖTZ J. The blood-brain barrier: Physiology and strategies for drug delivery [J]. Adv Drug Deliv Rev, 2020, 165-166: 1-14.Doi: 10.1016/j.addr.2019.11.009.
[35] PENG X, LUO Z, HE S, et al. Blood-brain barrier disruption by lipopolysaccharide and sepsis-associated encephalopathy [J]. Front Cell Infect Microbiol, 2021: 1083.Doi 10.3389/fcimb.2021.768108.
[36] YAU B, HUNT N H, MITCHELL A J, et al. Blood-brain barrier pathology and CNS outcomes in streptococcus pneumoniae meningitis [J]. Int J Mol Sci, 2018, 19(11):3555. Doi: 10.3390/ijms19113555.
[37] GOFMAN N, TO K, WHITMAN M, et al. Successful treatment of ventriculitis caused by and carbapenem-resistant with i.v. ceftazidime-avibactam and intrathecal amikacin [J]. Am J Health Syst Pharm, 2018, 75(13):953-957.
[38] YASMIN M, HANRAHAN J, MARSHALL S, et al. Using therapeutic drug monitoring to treat KPC-producing klebsiella pneumoniae central nervous system infection with ceftazidime/avibactam [J]. Open Forum Infect Dis, 2020, 7(9):ofaa349. Doi: 10.1093/ofid/ofaa349.
[39] HOLYK A, BELDEN V, LEE J J, et al. Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report [J]. J Antimicrob Chemother, 2018, 73(1):254-256.
[40] XIPELL M, BODRO M, MARCO F, et al. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa [J]. Int J Antimicrob Agents. 2017, 49(2):266-268.
[41] GATTI M, VIRGILI G, COJUTTI P G, et al. Real-time optimization of pharmacodynamic target attainment at infection site during treatment of post-neurosurgical ventriculitis caused by carbapenem-resistant gram negatives with ceftazidime-avibactam-based regimens: a report of two cases [J]. Microorganisms, 2022, 10(1):154. Doi: 10.3390/microorganisms10010154.
[42] GONCETTE V, LAYIOS N, DESCY J, et al. Continuous infusion, therapeutic drug monitoring and outpatient parenteral antimicrobial therapy with ceftazidime/avibactam: a retrospective cohort study [J]. J Glob Antimicrob Resist, 2021, 26: 15-19. Doi: 10.1016/j.jgar.2021.04.015.
[43] BUNING A W, HODIAMONT C J, LECHNER N M, et al. Population pharmacokinetics and probability of target attainment of different dosing regimens of ceftazidime in critically ill patients with a proven or suspected pseudomonas aeruginosa infection [J]. Antibiotics (Basel), 2021, 10(6):612. Doi: 10.3390/antibiotics10060612.
[44] VEIGA R P, PAIVA J A. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients [J]. Crit Care, 2018, 22(1):233. Doi: 10.1186/s13054-018-2155-1.
[45] ULLDEMOLINS M, VAQUER S, LLAURADÓ-SERRA M, et al. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy [J]. Crit Care, 2014, 18(3):227. Doi: 10. 1186/cc13938.
[46] GAIBANI P, GATTI M, RINALDI M, et al. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient [J]. Int J Infect Dis, 2021, 113: 213-217. Doi: 10.1016/j.ijid.2021.10.028.